Molecular Diagnosis & Therapy

, Volume 15, Issue 2, pp 83–102

Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases

Current Progress and Clinical Potential
Current Opinion

DOI: 10.1007/BF03256398

Cite this article as:
Noelker, C., Hampel, H. & Dodel, R. Mol Diag Ther (2011) 15: 83. doi:10.1007/BF03256398


Biomarker research is a rapidly advancing field in medicine. Recent advances in genomic, genetic, epigenetic, neuroscientific, proteomic, and metabolomic knowledge and technologies have opened the way to thriving research. In the most general sense, a biomarker refers to any useful characteristic that can be measured and used as an indicator of a normal biologic process, a pathogenic process, or a pharmacologic response to a therapeutic agent. Despite the extensive resources concentrated on this area, there are very few biomarkers currently available that qualify and are satisfactorily validated for mental disorders, and there is still a major lack of biomarkers for typifying neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. This article provides an overview of this field of research and focuses on recent advances in biomarker research in Alzheimer’s disease and Parkinson’s disease.

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Department of NeurologyPhilipps-University MarburgMarburgGermany
  2. 2.Department of Psychiatry, Psychosomatic Medicine and PsychotherapyUniversity of FrankfurtFrankfurt/MainGermany

Personalised recommendations